Tracey A Day on Muck Rack

Tracey A Day

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tracey A

Contact Tracey A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial - The Lancet Respiratory Medicine

|
By Tracey A Day, Adam Penn-Nicholson, Cape Town
| The Lancet
Summary Background A therapeutic vaccine that prevents recurrent tuberculosis would be a major advance in the development of shorter treatment regimens. We aimed to assess the safety and immunogenicity of the ID93 + GLA-SE vaccine at various doses and injection schedules in patients with previously treated tuberculosis. Methods This randomised, double-blind, placebo-controlled, phase 2a trial was conducted at three clinical sites near Cape Town, South Africa.
Open in Who Shared Issue with article?

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial - The Lancet Respiratory Medicine

|
By Adam Penn-Nicholson, Erica Smit, Michele Tameris, Tracey A Day
| The Lancet
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresFigure 1(A) Study design schematic and (B) trial profileParticipants missing the third injection either withdrew consent, were lost to follow up, were pregnant, or missed the injection visit. Participants were in follow up for 6 months after the third injection.
Open in Who Shared Issue with article?
See all 2 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Tracey A

Contact Tracey A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified